IMAGE IN CARDIOLOGY

DOI: 10.4244/EIJV10I11A224

Serial optical coherence tomography of drug-eluting stent in-stent restenosis treated with the Absorb bioresorbable scaffold: an effective treatment?

Vasim Farooq, MBChB, MRCP, PhD; Mamas A. Mamas, MA, DPhil, BM BCh, MRCP; Douglas G. Fraser, MB BChir, BA, FRCP, DM; Magdi El-Omar, BSc, MBBS, MRCP, MD; Bernard Clarke, BSc, MBChB, MD, FRCP, FESC, FACC; Farzin Fath-Ordoubadi*, BSc, MB BChir, MD, FRCP

Severe drug-eluting stent in-stent restenosis (ISR) in the left anterior descending (LAD) artery was treated with a 3.0×28 mm Absorb bioresorbable vascular scaffold (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA). Seven-month scheduled angiography demonstrated no significant change with a fully patent treated LAD vessel with TIMI (Thrombolysis In Myocardial Infarction) 1 flow in the septal branch (Figure 1A).

Figure 1. Baseline and seven-month coronary angiography and optical coherence tomography of drug-eluting stent-in-stent restenosis treated with the Absorb BVS.

Potential advantages of the Absorb BVS for the treatment of ISR include avoidance of multiple permanent metallic stent layers, limus-based drug elution, and allowances to treat disease beyond the stent margins.

Seven-month optical coherence tomography demonstrated incomplete healing, with a lack of a smooth luminal contour and multiple uncovered Absorb struts overlapped with metallic struts (Figure 1B). The thicker Absorb struts (156 μm), similar in thickness to first-generation drug-eluting stents, create alterations in shear stress (high shear stress on top of the strut and low shear stress behind the strut) that predisposes to a greater neointimal response and possible triggering of platelet aggregation. Furthermore, porcine studies have shown healing of overlapping Absorb BVS (strut thickness >300 microns) to be delayed at 30 days and completed at 90 days (equivalent to approximately six and 18 months in humans, respectively). In addition, the possibility of localised drug toxicity leading to delayed healing cannot be excluded: for example, most of the antiproliferative drug remains sequestered in the durable polymer of the first-generation TAXUS drug-eluting stent (Boston Scientific, Marlborough, MA, USA). Randomised trials are required to establish the potential safety and efficacy of the Absorb BVS for the treatment of ISR and the duration of dual antiplatelet therapy.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 10 Number 11
Mar 20, 2015
Volume 10 Number 11
View full issue


Key metrics

Suggested by Cory

IMAGE IN CARDIOLOGY

10.4244/EIJV11I1A14 May 19, 2015
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity
Azzalini L et al
free

10.4244/EIJV11I12A259 Mar 18, 2016
Oversized post-dilatation of current bioresorbable vascular scaffolds: kill or cure?
von Birgelen C and Basalus M
free

10.4244/EIJV13I7A115 Sep 20, 2017
Bioresorbable scaffolds: reflections after a setback - losing a battle does not mean losing the war!
Colombo A and Azzalini L
free

10.4244/EIJV14I9A176 Oct 12, 2018
The future of vascular restoration therapy
Sabaté M
free
Trending articles
200.45

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
154.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
92.95

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
47.4

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
43.65

Clinical research

10.4244/EIJ-D-23-00590 Dec 4, 2023
Prognostic impact of cardiac damage staging classification in each aortic stenosis subtype undergoing TAVI
Nakase M et al
free
36.5

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
34.75

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved